TAK-438 Enters into Phase III Clinical Trials in Japan for the Treatment of Acid-related Diseases
TAK-438, originated by Takeda, is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid secretion by inhibiting the binding of potassium ion (K+) to H+, K+-ATPase (proton pump). It has a different mechanism of action from proton pump inhibitors (“PPIs”).
TAK-438 is anticipated to have, in clinical use, a more potent inhibitory effect on gastric acid secretion, a faster onset of action, and a longer lasting effect than PPIs. The Phase III clinical trials in Japan are multi-centric, and designed to evaluate the safety and efficacy of TAK-438 for diseases such as gastric ulcer, duodenal ulcer and reflux esophagitis.
“There are still many patients with acid-related diseases who have severe conditions, or not responsive to PPI therapy,” said Nancy Joseph-Ridge, M.D., Corporate Officer and General Manager, Pharmaceutical Development Division of Takeda. “Leveraging our extensive experience in the area of gastroenterology, we will efficiently conduct the development activities of TAK-438 so that we can offer another potential new treatment option to these patients as quickly as possible.”
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.